Ruxolitinib as salvage therapy for neonatal HLH in preterm twins born to a mother with adult‐onset Still's disease
Pediatrics International · 2025-01 · 67 (1)
DOI: 10.1111/ped.70203 ↗At a glance
Journal article in Pediatrics International, published online on 2025-09-16. Written by Chihiro Nakazawa and 6 co-authors. Institution: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. 7 references.
Abstract (original language)
The authors declare no conflict of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Subjects
Author keywords
Authors and institutions
- Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
- Center for Medical Genetics, Shinshu University Hospital, Matsumoto, Japan.
- Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Pediatrics and Developmental Biology, Institute of Science, Tokyo, Japan.
ORCID profiles: Yukihide Miyosawa, Masaki Shimizu, Yozo Nakazawa
Cite
APA
Nakazawa, C., Maruyama, Y., Kamiya, M., Miyosawa, Y., Hatano, M., Shimizu, M., & Nakazawa, Y. (2025). Ruxolitinib as salvage therapy for neonatal HLH in preterm twins born to a mother with adult‐onset Still's disease. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70203
Vancouver
Nakazawa C, Maruyama Y, Kamiya M, Miyosawa Y, Hatano M, Shimizu M, et al. Ruxolitinib as salvage therapy for neonatal HLH in preterm twins born to a mother with adult‐onset Still's disease. Pediatrics International. 2025;67(1). doi:10.1111/ped.70203
BibTeX
@article{Nakazawa2025,
author = {Nakazawa, Chihiro and Maruyama, Yuta and Kamiya, Motoko and Miyosawa, Yukihide and Hatano, Maho and Shimizu, Masaki and Nakazawa, Yozo},
title = {Ruxolitinib as salvage therapy for neonatal HLH in preterm twins born to a mother with adult‐onset Still's disease},
journal = {Pediatrics International},
year = {2025},
volume = {67},
number = {1},
doi = {10.1111/ped.70203}
}
EUVIMED